JPM-OEt|262381-84-0|-陌孚医药/Medlife

您当前的位置：

JPM-OEt

目录号: PL15164 纯度: ≥99%

CAS No. :262381-84-0

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	JPM-OEt
中文别名	JPM 565 乙基酯
英文名称	JPM-OEt
英文别名	2-Oxiranecarboxylicacid,3-[[[(1S)-1-[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-,ethyl ester, (2S,3S)-;ethyl (2S,3S)-3-{[(2S)-1-{[2-(4-hydroxyphenyl)ethyl]amino}-3-methyl-1-oxopentan-2-yl]carbamoyl}oxirane-2-carboxylate;2-Oxiranecarboxylicacid,3-[[[(1S)-1-[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-,ethyl ester, (;JPM-OEt;N-[[L-TRANS-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL]-L-LEUCYL-3-(P-HYDROXYPHENYL)ETHYLAMIDE;XSC-2;(2S,3S)-3-[[[(1S)-1-[[[2-(4-Hydroxyphenyl)ethyl]amino]carbonyl]-3-methylbutyl]amino]carbonyl]-2-oxiranecarboxylic acid ethyl ester;JPM 565-OEt;ethyl (2S,3S)-3-[[(2S)-1-[2-(4-hydroxyphenyl)ethylamino]-3-methyl-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate;CID644294;BDBM36334;JPM 565;2-oxiranecarboxylic acid, 3-[[[(1S,2S)-1-[[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-2-methylbutyl]amino]carbonyl]-, ethyl ester, (2S,3S)-;3-(Ethoxycarbonyl)-N-(1-hydroxy-1-{[2-(4-hydroxyphenyl)ethyl]imino}-3-methylpentan-2-yl)oxirane-2-carboximidic acid;Oxiranecarboxylic acid, 3-[[[(1S)-1-[[[2-(4-hydroxyphenyl)eth
Cas No.	262381-84-0
分子式	C₂₀H₂₈N₂O₆
分子量	392.45
包装储存	4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

产品详情	JPM-OEt 是一种广谱的半胱氨酸组织蛋白酶 (cysteine cathepsin) 抑制剂。JPM-OEt 在活性位点共价结合，并且不可逆地抑制半胱氨酸组织蛋白酶家族。具有抗肿瘤活性。
生物活性	JPM-OEt is a broad spectrum cysteine cathepsin inhibitor. JPM-OEt binds covalently in the active site, and irreversibly inhibits the cysteine cathepsin family. Antitumor activity.
性状	Solid
体内研究(In Vivo)	JPM-OEt (50 mg/kg; i.p.; daily for 30 days) reduces tumor cathepsin B activity significantly. JPM-OEt (50 mg/kg; i.p.; twice daily for 4 weeks) leads to tumor regression in the RIP1-Tag2 (RT2) mouse model of pancreatic islet cell tumorigenesis. JPM-OEt (50 mg/kg; i.p.; daily from 63 to 98 days) causes a significant delay in the increase of tumour burden during the first 2 weeks of treatment. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	4°C, protect from light In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
参考文献	[1]. Withana NP, et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012 Mar 1;72(5):1199-209. [2]. Bell-McGuinn KM, et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007 Aug 1;67(15):7378-85.

溶解度数据	In Vitro: DMSO : 125 mg/mL (318.51 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品